Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promis-ing treatment for PSC that needs to be further studied in randomized trials.
Abstract
Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promis-ing treatment for PSC that needs to be further studied in randomized trials.
참고문헌 (10)
- Tabibian JH, "Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies", Scand J Gastroenterol, 49, pp.901~908 (2014)
- Björnsson E, "The natural history of small-duct primary sclerosing cholangitis", Gastroenterology, 134, pp.975~980 (2008)
- Lindor KD, "American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis", Am J Gastroenterol, 110, pp.646~659 (2015)
- Miloh T, "A retrospective single-center review of primary sclerosing cholangitis in children", Clin Gastroenterol Hepatol, 7, pp.239~245 (2009)
- Feldstein AE, "Primary sclerosing cholangitis in children: a long-term follow-up study", Hepatology, 38, pp.210~217 (2003)
- Lindor KD, "McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis", Hepatology, 50, pp.808~814 (2009)
- Abarbanel DN, "Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis", J Clin Immunol, 33, pp.397~406 (2013)
- Davies YK, "Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic", J Pediatr Gastroenterol Nutr, 47, pp.61~67 (2008)
- Tabibian JH, "Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study", Aliment Pharmacol Ther, 37, pp.604~612 (2013)
- Davies YK, "Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin", Case Rep Transplant, 2013, pp.314292~ (2013)